Drug Profile
Infliximab biosimilar - Hisun BioRay Pharmaceutical
Alternative Names: HS-626Latest Information Update: 12 Oct 2022
Price :
$50
*
At a glance
- Originator Hisun BioRay
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 10 Oct 2022 No development reported - Phase-III for Plaque psoriasis in China (IV)
- 29 Jun 2020 Hisun BioRay Pharmaceutical completes enrolment in its phase III trial for Plaque psoriasis in China (ChiCTR2000034243)
- 29 Jun 2020 Phase-III clinical trials in Plaque psoriasis in China (IV) (ChiCTR2000034243)